Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …

This analysis explores the impact of early cytogenetic and molecular responses on the
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase …

Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is
resistant to available treatment, although it is associated with arterial occlusion. We …

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …

In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

Purpose Deep molecular response (MR4. 5) defines a subgroup of patients with chronic
myeloid leukemia (CML) who may stay in unmaintained remission after treatment …

Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that
is expressed in the majority of anaplastic large-cell lymphomas. ALK is a receptor protein …

More than 95% of the 20,000 to 25,000 transcribed human genes undergo alternative RNA
splicing, which increases the diversity of the proteome. Isoforms derived from the same gene …

We explored the impact of early molecular response (EMR; BCR-ABL≤ 10% on the
international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly …